A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Davendra Sohal(University of Cincinnati), Weijing Sun(University of Kansas Medical Center), Antonia R. Sepulveda(George Washington University), Ursina Teitelbaum(University of Pennsylvania), Mary Carberry(University of Pennsylvania), Paul Wissel(University of Pennsylvania), Takeshi Uehara(Shinshu University Hospital), Mona Jacobs-Small(University of Pennsylvania), Bruce J. Giantonio(Northwestern University), Nevena Damjanov(University of Pennsylvania), Kristine Mykulowycz(University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania)
Cited by 89
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541